Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.

Cancer research communications - 30 Apr 2024

Garmezy Benjamin, Borad Mitesh J, Bahleda Rastilav, Perez Cesar A, Chen Li-Tzong, Kato Shumei, Oh Do-Youn, Severson Paul, Tam Betty Y, Quah Cheng S, Harding James J

Abstract excerpt

PURPOSE: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small-molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations. EXPERIMENTAL DESIGN: A first-in-human, phase I study of KIN-3248 was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Maximum Tolerated Dose

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Receptor, Fibroblast Growth Factor, Type 3

Source

Open in PubMed Open full text

Identifiers

PMID: 38602417
DOI: 10.1158/2767-9764.CRC-24-0137
PMCID: PMC11060137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.PMID 38602417Read ↗

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read ↗

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.Semantic proximity Read ↗

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.Semantic proximity Read ↗

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.Semantic proximity Read ↗

Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations.Semantic proximity Read ↗

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Semantic proximity Read ↗

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.Semantic proximity Read ↗

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read ↗

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.Semantic proximity Read ↗

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Semantic proximity Read ↗

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Semantic proximity Read ↗

Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.